AL002 for Alzheimer's Disease
Trial Summary
What is the purpose of this trial?
This trial tests AL002, a drug for early Alzheimer's disease, in people who were part of an earlier study. It aims to check if AL002 is safe and effective over time.
Do I have to stop taking my current medications for the AL002 trial?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial team for guidance.
How does the drug AL002 differ from other Alzheimer's treatments?
AL002 is unique because it targets a specific sequence (31-35) in the amyloid beta protein, which is believed to be a key area responsible for the neurotoxicity seen in Alzheimer's disease. This approach may offer a novel way to protect neurons and improve memory and learning by preventing damage caused by amyloid beta.12345
Research Team
TBD TBD
Principal Investigator
Eligibility Criteria
This trial is for individuals with Early Alzheimer's Disease who completed the AL002-2 study, can consent to participate, and have a caregiver involved at least 10 hours weekly. Those unable to consent or discontinued from the previous study due to safety cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AL002 every 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AL002
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alector Inc.
Lead Sponsor
AbbVie
Industry Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois